Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.30−0.02 (-0.60%)
Close on Nov 18, 2026Market cap $263.35MP/E –Yield –
Prelude Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Prelude Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$33.26M. For fiscal 2025 it was -$56.37M. The highest annual figure on record is -$26.45M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$56.37M | – |
| FY2024 | Dec 31, 2024 | -$103.65M | – |
| FY2023 | Dec 31, 2023 | -$110.58M | – |
| FY2022 | Dec 31, 2022 | -$86.75M | – |
| FY2021 | Dec 31, 2021 | -$85.85M | – |
| FY2020 | Dec 31, 2020 | -$46.80M | – |
| FY2019 | Dec 31, 2019 | -$26.45M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.57M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.69M | – |
| Q4 FY2025 | Dec 31, 2025 | $23.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.80M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.36M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$28.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.32M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.85M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.29M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.18M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.68M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.67M | – |
See a number that looks wrong?